3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
6
Observational
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
16
Carcinoma, Hepatocellular
11
Stomach Neoplasms
6
Neoplasms
5
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Myositis
2
Lung Neoplasms
2
Cholangiocarcinoma
2
Vascular Complications
1
Sjogren's Syndrome
1
Scleroderma, Systemic
1
Sarcopenia
1
Recurrence
1
Rectal Neoplasms
1
Plaque, Atherosclerotic
1
Pathologic Complete Response
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Mouth Neoplasms
1
Metastatic Colorectal Adenocarcinoma
1
Melanoma
1
Lupus Erythematosus, Systemic
1
Lung Diseases, Interstitial
1
Liver Neoplasms
1
Influenza, Human
1
Immune-Related Adverse Events
1
Interventions
Sunitinib
17
Sorafenib
16
pazopanib
7
cabozantinib
7
Axitinib
7
Blood Specimen Collection
6
Bevacizumab
6
avelumab
5
Immunohistochemistry
5
temsirolimus
4
pembrolizumab
3
Watchful Waiting
3
Specimen Handling
3
Immunotherapy
3
Gene Expression Profiling
3
Everolimus
3
Urine Specimen Collection
2
Nephrectomy
2
Magnetic Resonance Spectroscopy
2
Magnetic Resonance Imaging
2
Flow Cytometry
2
Data Collection
2
Amplified Fragment Length Polymorphism Analysis
2
trastuzumab deruxtecan
1
lenvatinib
1
fluoroazomycin arabinoside
1
enfortumab vedotin
1
darolutamide
1
atezolizumab
1
aldesleukin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Carcinoma, Renal Cell
×
Immune Checkpoint Inhibitors
×
Clear all
NCT05037825
2022-04-27
PARADIGM
VastBiome
Recruiting
800 enrolled